Guggenheim Forecasts Strong Price Appreciation for Pfizer (NYSE:PFE) Stock

Pfizer (NYSE:PFE) had its target price increased by equities researchers at Guggenheim from $31.00 to $33.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim‘s price objective would indicate a potential upside of 12.32% from the stock’s current price.

Several other equities analysts also recently issued reports on PFE. HSBC raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. JPMorgan Chase & Co. increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 9th. BMO Capital Markets decreased their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Cantor Fitzgerald raised their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Finally, Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Six investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $30.39.

Pfizer Price Performance

Shares of PFE traded down $0.50 during midday trading on Thursday, hitting $29.38. The company’s stock had a trading volume of 48,291,518 shares, compared to its average volume of 30,697,644. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer has a one year low of $23.62 and a one year high of $31.44. The stock has a market capitalization of $167.46 billion, a price-to-earnings ratio of 41.97, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31. The company’s fifty day simple moving average is $28.74 and its two-hundred day simple moving average is $26.90.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. The business had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.87 EPS. As a group, equities analysts expect that Pfizer will post 3.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently bought and sold shares of PFE. Retirement Wealth Solutions LLC grew its holdings in Pfizer by 144.6% during the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 509 shares during the period. Keb Asset Management LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at about $26,000. Field & Main Bank bought a new stake in shares of Pfizer during the 2nd quarter valued at about $27,000. Bullseye Investment Management LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $28,000. Finally, Timbuktu Capital Management LLC acquired a new stake in Pfizer during the second quarter worth approximately $29,000. Institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

Pfizer Company Profile